Delivery Order SPE2DB24D2013-SPE2DB26FCGQZ
- Not listed
- The Defense Logistics Agency awarded a $2,400.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Losartan-HCTZ 100-12.5 mg, a common antihypertensive medication combining a angiotensin II receptor blocker with a thiazide diuretic. The order was competitively awarded with no set-aside designation and is scheduled for completion by July 21, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $2,851.36 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity. This competitively awarded, firm fixed-price contract is categorized as a delivery order with an ultimate completion date of September 17, 2025, and carries no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,491.29 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,934.36 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on September 16, 2025. This firm fixed price delivery order, with a completion date of September 17, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. The pharmaceutical product...
- The Defense Logistics Agency awarded a $14,962.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90-tablet supplies of Losartan-HCTZ 100-12.5 mg tablets, with performance in Conshohocken, Pennsylvania and completion by September 15, 2025. This non-set-aside award was competitively procured and represents a routine pharmaceutical supply delivery under the company's existing contract vehicle with DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered...
- The Defense Logistics Agency awarded a $6,949.42 delivery order to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on October 24, 2025, with an ultimate completion date of October 27, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price terms and is classified as a delivery order, indicating it is issued against a larger indefinite delivery vehicle. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $4,646.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90-count tablets of Losartan-HCTZ 50-12.5 mg, a combination antihypertensive medication used to treat high blood pressure. The contract, which was awarded on October 21, 2025, with an ultimate completion date of October 22, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $2,430.48 by the Defense Logistics Agency on September 8, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count packages). The contract carries a firm fixed price structure with an ultimate completion date of September 9, 2025, and represents a non-set-aside award. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a quantity of 90 units, with a firm fixed price ceiling value of $1,620.32. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 29, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a delivery order under a larger contract...
- The Defense Logistics Agency awarded a $2,162.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Losartan-HCTZ 50-12.5 mg tablets (90-count supply) on August 7, 2025, with a completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB26FCGQZDelivery Order
The Defense Logistics Agency awarded a $1,279.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90-count tablets of Losartan-HCTZ 50-12.5 mg, a combination antihypertensive medication. The order was competitively awarded without a set-aside designation and is scheduled for completion by October 27, 2025. AmerisourceBergen will perform the delivery from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare systems globally. The company's federal contract portfolio demonstrates extensive experience fulfilling DLA requirements across multiple therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible procurement mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 10/24/25 |